Subscribe To

Price Alert Latest News Economic Calendar News

PHVS / Pharvaris shares soar on positive top-line Phase 2 data from RAPIDe-1 study as it releases 3Q results

Pharvaris (NASDAQ:PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, has announced positive top-line data from its RAPIDe-1 Phase 2 clinical study, sending its shares soaring in early trade. Releasing the results alongside its third-quarter financials, the Zug, Switzerland-based company said the data demonstrates statistically significant results of PHVS416 as an oral on-demand treatment for HAE attacks. Read More

Demo Live Account See Partner Details

Content Topics

Pharvaris

Soar

Positive

Top

Line

Phase

Data

From

Top line

Rapide 1

Releases

Results

Stock

PHVS

Posted: Dec 8 2022, 11:34

Author Name: Proactive Investors

PHVS News

By GlobeNewsWire
October 13, 2023

Pharvaris To Present at the APAAACI 2023 International Conference

ZUG, Switzerland, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor a

By GlobeNewsWire
October 4, 2023

Pharvaris To Present at the CIIC Fall 2023 Conference

ZUG, Switzerland, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor a

By GlobeNewsWire
September 19, 2023

Pharvaris To Participate in the 2023 Cantor Global Healthcare Conference

ZUG, Switzerland, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor

By GlobeNewsWire
September 6, 2023

Pharvaris To Present at the 18th German Allergy Congress

ZUG, Switzerland, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor

By GlobeNewsWire
September 6, 2023

Pharvaris To Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

ZUG, Switzerland, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor

By Seeking Alpha
July 27, 2023

Pharvaris: FDA Lifts Clinical Hold, Progresses HAE Drug Development

Pharvaris, a clinical-stage company, has reported a cash position of €135 million as of March 31, 2023, indicating an operational runway of approxim

By The Motley Fool
June 27, 2023

Why Shares of Pharvaris N.V. Are Up Tuesday

Pharvaris has only one drug, deucrictibant, in its pipeline. Deucrictibant is being examined to treat hereditary angioedema (HAE), which can cause pai

By GlobeNewsWire
March 2, 2023

Pharvaris to Present in Upcoming March Investor Conferences

ZUG, Switzerland, March 02, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.